102 related articles for article (PubMed ID: 28402273)
1. Serum IL-33 level is a predictor of progression-free survival after chemotherapy.
Hu W; Wu C; Li X; Zheng Z; Xie Q; Deng X; Jiang J; Wu C
Oncotarget; 2017 May; 8(21):35116-35123. PubMed ID: 28402273
[TBL] [Abstract][Full Text] [Related]
2. Serum IL-17 levels can be diagnostic for gastric cancer.
Karabulut M; Usul Afsar C; Serimez M; Karabulut S
J BUON; 2019; 24(4):1601-1609. PubMed ID: 31646815
[TBL] [Abstract][Full Text] [Related]
3. Serum neural precursor cell-expressed, developmentally down regulated 9 (NEDD9) level may have a prognostic role in patients with gastric cancer.
Karabulut M; Alis H; Afsar CU; Karabulut S; Kocatas A; Oguz H; Aykan NF
Biomed Pharmacother; 2015 Jul; 73():140-6. PubMed ID: 26211595
[TBL] [Abstract][Full Text] [Related]
4. [Effect of early intestinal dripping of jianpi tongli Chinese herbs on serum level IL-2, sIL-2R and IL-12 in patients with gastric cancer after operation].
Yu QS; Liu Y; Hou Y; Zhang F; Yi W; Wang X; Shuai J
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Aug; 25(8):710-3. PubMed ID: 16152828
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
7. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer.
Saito H; Tsujitani S; Ikeguchi M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):253-8. PubMed ID: 10202282
[TBL] [Abstract][Full Text] [Related]
8. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
el Aziz LM
Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
[TBL] [Abstract][Full Text] [Related]
11. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of Chemotherapy with Trastuzumab in Advanced Gastric Cancer].
Kawada J; Nakatsuka R; Motoori M; Miyazaki S; Danno K; Kubota M; Matsuda C; Nishikawa K; Fujitani K; Iwase K; Tsujinaka T; Tanaka Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2091-3. PubMed ID: 26805274
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer.
Graziano F; Ruzzo A; Santini D; Humar B; Tonini G; Catalano V; Berardi R; Pizzagalli F; Arduini F; Bearzi I; Scartozzi M; Cascinu S; Testa E; Ficarelli R; Magnani M
J Clin Oncol; 2005 Apr; 23(10):2339-45. PubMed ID: 15800325
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
15. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
[TBL] [Abstract][Full Text] [Related]
16. Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?
Sedef AM; Köse F; Sümbül AT; Doğan Ö; Beşen AA; Tatlı AM; Mertsoylu H; Sezer A; Muallaoğlu S; Özyılkan Ö; Abalı H
Med Oncol; 2015 Feb; 32(2):476. PubMed ID: 25572818
[TBL] [Abstract][Full Text] [Related]
17. High plasma sST2 levels in gastric cancer and their association with metastatic disease.
Bergis D; Kassis V; Radeke HH
Cancer Biomark; 2016; 16(1):117-25. PubMed ID: 26835712
[TBL] [Abstract][Full Text] [Related]
18. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
Bilici A; Ustaalioglu BB; Ercan S; Orcun A; Seker M; Salepci T; Gumus M
Cancer Chemother Pharmacol; 2011 Aug; 68(2):309-16. PubMed ID: 20967544
[TBL] [Abstract][Full Text] [Related]
19. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
Liu K; Li G; Fan C; Zhou C; Li J
Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma.
Wang LS; Chow KC; Li WY; Liu CC; Wu YC; Huang MH
Clin Cancer Res; 2000 Apr; 6(4):1445-51. PubMed ID: 10778976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
